Samsung Biologics just offered 1.46 billion Swiss francs for PolyPeptide Group. That's $1.8 billion in American money. The company manufactures peptides. In Switzerland.
You know what a peptide is. You learned it once. Forgot it immediately. Googled it three years later when your protein powder label mentioned it. Still don't know. Don't care either. Samsung Biologics knows though. They know so well they're dropping nearly two billion dollars on a Swiss company that makes them.
All cash. Not stock. Not a merger. Not shares plus earnouts structured by McKinsey guys who bill $900 an hour to make PowerPoints. Cash. The kind of offer that makes investment bankers weep because there's nothing left to arbitrage.
Some retail trader in Michigan just saw this headline. He's opening his Robinhood app right now. He's typing Samsung into the search bar. He's buying shares of Samsung Electronics. Wrong company. He'll figure that out in four months when his portfolio is down 18% and his wife asks why they can't afford the good cereal anymore.
PolyPeptide Group makes ingredients for drugs. Samsung Biologics makes biologics. The synergy is so obvious it barely qualifies as strategic vision. It's just vertical integration wearing a suit. Some consultant will still get paid $400,000 to write integration roadmaps that say "combine the things" in 47 different ways.
The Swiss are selling. The Koreans are buying. The franc converts to the dollar. The peptides keep getting manufactured. Your technical indicators saw none of this coming and will predict none of what happens next. The 50-day moving average on PolyPeptide's stock could've formed a perfect middle finger and it wouldn't have told you Samsung was writing a check for $1.8 billion.
But sure. Your MACD divergence called it.
Photo by on Unsplash
Leave a Comment